Market revenue in 2023 | USD 61.7 million |
Market revenue in 2030 | USD 93.8 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 62.56% in 2023. Horizon Databook has segmented the Kuwait asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Several multinational and regional pharmaceutical companies are likely to be active in the Kuwaiti market, offering asthma therapeutics drugs. In addition, several multinational players are focusing on developing and distributing asthma drugs in the Kuwait market due to the unmet medical needs in the country.
For instance, the estimated prevalence rates indicate that asthma affects 15% of adults and 18% of children. In terms of financial implications, the annual treatment cost, excluding medications, stands at USD 107 million (KD 29,946,776) for adults and USD 86 million (KD 24,295,439) for children.
Furthermore, government initiatives and investments in anti-infective and pharmaceuticals are propelling market growth. For instance, in April 2023, Kuwait University (KU), under the auspices of the Patent & Intellectual Property Office within the University’s Vice President’s Office for Research, successfully obtained a patent for developing a pharmaceutical to treat asthma and allergy patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account